

CAPLIN POINT LABORATORIES LIMITED  
Registered Office: "Narbhavi", # 3, Lakshmanan Street, T. Nagar, Chennai 600 017  
UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th SEPTEMBER 2013

Part I Particulars	Unaudited	Audited (Refer Note No.5)	Unaudited	Audited	Unaudited	Audited
	Three months ended		Year ended		Year ended	
	Sep 30, 2013	June 30, 2013	Sep 30, 2012	June 30, 2013	June 30, 2012	June 30, 2012
Rs. In Lakhs						
<b>1</b>	<b>Income</b>					
a.	Net Sales/ income from operations (Net of Excise Duty)	3,826.61	3,452.14	2,666.09	11,878.17	10,529.93
b.	Foreign Exchange Fluctuation Gain	149.23	141.04	277.92	-	-
c.	Share of profits in LLP	3,975.84	3,593.18	66.70	389.05	232.13
d.	Total			<b>3,010.71</b>	<b>12,267.22</b>	<b>10,762.06</b>
<b>2</b>	<b>Expenditure</b>					
a.	Cost of materials consumed	811.27	814.76	735.20	3,084.41	3,113.07
b.	Purchase of Stock-in-Trade	1,789.89	1,550.12	1,191.65	5,273.34	4,762.90
c.	Change in inventories of Finished Goods, work in progress and stock in trade	(112.59)	(19.05)	(4.12)	(106.97)	38.57
d.	Employees benefit expenses	266.30	234.80	189.09	796.54	614.14
e.	Depreciation	42.91	43.63	31.38	143.77	114.43
f.	Amortisation of Intangible Assets	2.30	0.74	0.27	1.55	1.07
g.	Foreign Exchange Fluctuation Loss	460.88	399.94	-	218.66	481.72
h.	Other Expenditure	254.98	242.17	198.91	847.36	703.75
i.	Total	3,515.95	3,267.11	2,342.38	10,258.66	9,829.65
<b>3</b>	<b>Profit (+)/Loss(-) from Operations before other income and finance cost and exceptional items (1-2)</b>	<b>459.89</b>	<b>326.07</b>	<b>668.33</b>	<b>2,008.56</b>	<b>932.41</b>
4	Other Income	48.08	30.32	74.93	173.30	238.95
<b>5</b>	<b>Profit (+)/Loss(-) from ordinary activities before finance cost and exceptional items (3+4)</b>	<b>507.97</b>	<b>356.39</b>	<b>743.26</b>	<b>2,181.86</b>	<b>1,171.36</b>
6	Finance cost	(3.54)	(15.15)	(10.52)	(30.06)	(87.69)
<b>7</b>	<b>Profit (+)/Loss(-) from Ordinary Activities after finance cost but before exceptional cost (5-6)</b>	<b>504.43</b>	<b>341.24</b>	<b>732.74</b>	<b>2,151.80</b>	<b>1,083.67</b>
8	Exceptional items	-	-	-	-	-
<b>9</b>	<b>Profit (+)/Loss(-) from Ordinary Activities before Tax (7-8)</b>	<b>504.43</b>	<b>341.24</b>	<b>732.74</b>	<b>2,151.80</b>	<b>1,083.67</b>
10	Provision for Taxation	(110.00)	(75.00)	(160.00)	(475.00)	(190.19)
	Provision for Taxation - earlier years	-	(8.56)	-	(8.56)	-
	Deferred Tax Provision	(15.00)	(93.56)	(25.81)	(232.32)	(93.76)
	Mat Credit Entitlement	-	(5.27)	-	(5.27)	18.79
<b>11</b>	<b>Net Profit (+)/Loss(-) from Ordinary Activities after tax (9-10)</b>	<b>379.43</b>	<b>158.85</b>	<b>546.93</b>	<b>1,430.65</b>	<b>818.51</b>
12	Extraordinary item (net of tax expense)	-	-	-	-	-
<b>13</b>	<b>Net Profit (+)/Loss(-) for the period (11-12)</b>	<b>379.43</b>	<b>158.85</b>	<b>546.93</b>	<b>1,430.65</b>	<b>818.51</b>
14	Paid up Equity Share Capital (Face value of the share - Rs 10/- each)	1,511.00	1,511.00	1,511.00	1,511.00	1,511.00
15	Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year	-	-	-	2,505.35	1,516.65
16	Earnings/(Loss) Per Share (EPS) (Not annualised)					
	(a) Basic/Diluted EPS before Extraordinary items (in Rupees)	2.51	1.05	3.62	9.47	5.42
	(b) Basic/Diluted EPS after Extraordinary items (in Rupees)	2.51	1.05	3.62	9.47	5.42

Part II	Select information for the Quarter ended 30th Sep 2013					
	Unaudited Sep 30, 2013	Audited June 30, 2013	Unaudited Sep 30, 2012	Audited June 30, 2013		2012
<b>A PARTICULARS OF SHARE HOLDING</b>						
17 Public Shareholding						
- Number of Shares	6,470,647	6,470,647	6,470,647	6,470,647	6,470,647	6,470,647
- Percentage of Shareholding	42.82%	42.82%	42.82%	42.82%	42.82%	42.82%
18 Promoters and promoter group Shareholding						
a) Pledged/Encumbered						
- Number of Shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
b) Non-encumbered						
- Number of Shares	8,639,353	8,639,353	8,639,353	8,639,353	8,639,353	8,639,353
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the company)	57.18%	57.18%	57.18%	57.18%	57.18%	57.18%
<b>B INVESTOR COMPLAINTS</b>	<b>3 months ended 30-09-2013</b>					
Particulars						
Pending at the beginning of the quarter		2				
Received during the quarter		7				
Disposed of during the quarter		9				
Remaining unresolved at the end of the quarter		Nil				

**Notes :**

- 1) The Company operates in one segment only.
- 2) The above consolidated unaudited financial results were considered and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 07th November 2013
- 3) The statutory auditors have carried out a limited review of the results for the quarter ended 30th September 2013.
- 4) The Consolidated financial results include the financial results of Argus Salud Pharma LLP in which controlling interest is held by the Company.
- 5) The figures for the quarter ended June 30, 2013 are the balancing figures between the audited figures in respect of the full financial year and the published figures (Unaudited) upto the third quarter of the previous financial year.
- 6) Prior year / period figures are regrouped / rearranged wherever necessary.

Place : Chennai  
Dated : 07.11.2013

M. Jayapal  
Managing Director



CAPLIN POINT LABORATORIES LIMITED  
Registered Office: "Narbavi", # 3, Lakshmanan Street, T. Nagar, Chennai 600 017  
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th SEPTEMBER 2013

Part I Particulars	Unaudited	Audited (Refer Note No.5)		Unaudited	Audited	Audited
	Sep 30, 2013	Three months ended Jun 30, 2013		Sep 30, 2012	Year ended June 30, 2013	Year ended June 30, 2012
	Rs. In Lakhs					
<b>1 Income</b>						
a. Net Sales/ income from operations (Net of Excise Duty)	4,093.18	3,912.46	2,714.52	12,702.83	10,706.86	
b. Foreign Exchange Fluctuation Gain	-	-	294.75	-	-	
c. Total	4,093.18	3,912.46	3,009.27	12,702.83	10,706.86	
<b>2 Expenditure</b>						
a. Cost of materials consumed	977.85	965.80	814.10	3,550.51	3,580.10	
b. Purchase of Stock-in-Trade	1,615.84	1,561.11	1,080.53	5,038.48	4,141.17	
c. Change in inventories of Finished Goods, work in progress and stock in trade	(102.30)	33.40	(3.34)	(124.26)	15.47	
d. Employees benefit expenses	276.43	245.37	195.98	826.98	634.82	
e. Depreciation	45.25	45.96	33.45	152.47	122.59	
f. Amortisation of Intangible Assets	2.30	0.74	0.27	1.55	1.07	
g. Foreign Exchange Fluctuation Loss	474.65	431.39	-	254.53	495.52	
h. Other Expenditure	291.62	282.41	225.92	968.33	774.92	
i. Total	3,581.63	3,566.18	2,346.92	10,668.59	9,765.66	
<b>3 Profit(+)/Loss(-) from Operations before other income and finance cost and exceptional items (1-2)</b>	<b>511.55</b>	<b>346.28</b>	<b>662.35</b>	<b>2,034.24</b>	<b>941.20</b>	
4 Other Income	55.25	38.49	86.01	210.03	265.48	
<b>5 Profit(+)/Loss(-) from ordinary activities before finance cost and exceptional items (3+4)</b>	<b>566.80</b>	<b>384.77</b>	<b>748.36</b>	<b>2,244.27</b>	<b>1,206.68</b>	
6 Finance cost	(3.66)	(15.28)	(10.52)	(30.24)	(89.44)	
<b>7 Profit(+)/Loss(-) from Ordinary Activities after finance cost but before exceptional cost (5-6)</b>	<b>563.15</b>	<b>369.49</b>	<b>737.84</b>	<b>2,214.03</b>	<b>1,117.24</b>	
8 Exceptional items	-	-	-	-	-	
<b>9 Profit(+)/Loss(-) from Ordinary Activities before Tax (7-8)</b>	<b>563.15</b>	<b>369.49</b>	<b>737.84</b>	<b>2,214.03</b>	<b>1,117.24</b>	
10 Provision for Taxation	(150.00)	(106.24)	(170.00)	(565.74)	(239.28)	
Provision for Taxation - earlier years	-	(8.56)	-	(8.56)	-	
Deferred Tax Provision	(15.00)	(93.56)	(25.81)	(232.32)	(93.76)	
Mat Credit Entitlement	-	(5.27)	-	(5.27)	18.79	
<b>11 Net Profit(+)/Loss(-) from Ordinary Activities after tax (9-10)</b>	<b>398.15</b>	<b>155.86</b>	<b>542.03</b>	<b>1,402.14</b>	<b>802.99</b>	
12 Extraordinary Item (net of tax expense)	-	-	-	-	-	
<b>13 Net Profit(+)/Loss(-) for the period (11-12)</b>	<b>398.15</b>	<b>155.86</b>	<b>542.03</b>	<b>1,402.14</b>	<b>802.99</b>	
14 Minority Interest	(1.51)	(1.42)	(0.67)	(3.76)	(2.34)	
<b>15 Net Profit(+)/Loss(-) for the period after minority interest (13-14)</b>	<b>396.65</b>	<b>154.44</b>	<b>541.36</b>	<b>1,398.38</b>	<b>800.65</b>	
16 Paid up Equity Share Capital (Face value of the share - Rs 10/- each)	1,511.00	1,511.00	1,511.00	1,511.00	1,511.00	
17 Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year	-	-	-	2,429.86	1,473.41	
18 Earnings/(Loss) Per Share (EPS) (Not annualised)						
(a) Basic/Diluted EPS before Extraordinary items (in Rupees)	2.63	1.02	3.58	9.25	5.30	
(b) Basic/Diluted EPS after Extraordinary items (in Rupees)	2.63	1.02	3.58	9.25	5.30	

Part II		Select information for the Quarter ended 30th Sept 2013					
		Unaudited Three months ended Sep 30, 2013	Audited Three months ended Jun 30, 2013	Unaudited Three months ended Sep 30, 2012	Audited Year ended June 30, 2013	Audited Year ended June 30, 2012	
<b>A</b>	<b>PARTICULARS OF SHARE HOLDING</b>						
19	Public Shareholding						
	- Number of Shares	6,470,647	6,470,647	6,470,647	6,470,647	6,470,647	
	- Percentage of Shareholding	42.82%	42.82%	42.82%	42.82%	42.82%	
20	Promoters and promoter group Shareholding						
	a) Pledged/Encumbered						
	- Number of Shares	Nil	Nil	Nil	Nil	Nil	
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	
	b) Non-encumbered						
	- Number of Shares	8,639,353	8,639,353	8,639,353	8,639,353	8,639,353	
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	
	- Percentage of shares (as a % of the total share capital of the company)	57.18%	57.18%	57.18%	57.18%	57.18%	
<b>B</b>	<b>INVESTOR COMPLAINTS</b>	<b>3 months ended 30-09-2013</b>					
	Particulars						
	Pending at the beginning of the quarter		2				
	Received during the quarter		7				
	Disposed of during the quarter		9				
	Remaining unresolved at the end of the quarter		Nil				

**Notes :**

- 1) The Company operates in one segment only.
- 2) The above consolidated unaudited financial results were considered and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 07th November 2013
- 3) The statutory auditors have carried out a limited review of the results for the quarter ended 30th September 2013.
- 4) The Consolidated financial results include the financial results of Argus Salud Pharma LLP in which controlling interest is held by the Company.
- 5) The figures for the quarter ended June 30, 2013 are the balancing figures between the audited figures in respect of the full financial year and the published figures (Unaudited) upto the third quarter of the previous financial year.
- 6) Prior year / period figures are regrouped / rearranged wherever necessary.

Place : Chennai  
Dated : 07.11.2013

  
M. Jayapal  
Managing Director